GSK
1,050 hedge funds and large institutions have $18.2B invested in GSK in 2026 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 378 increasing their positions, 347 reducing their positions, and 87 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 378 | Existing positions reduced: 347
8% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 87
1% more funds holding
Funds holding: 1,043 → 1,050 (+7)
1.41% less ownership
Funds ownership: 18.71% → 17.3% (-1.4%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
15% less call options, than puts
Call options by funds: $136M | Put options by funds: $159M
65% less capital inflows, than outflows
Capital inflows: $827M | Capital outflows: $2.35B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$140M |
| 2 |
JP Morgan Chase
New York
|
+$79.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$63.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$53.9M |
| 5 |
NewEdge Advisors
New Orleans,
Louisiana
|
+$45.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$553M |
| 2 |
Holocene Advisors
New York
|
-$305M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$272M |
| 4 |
Morgan Stanley
New York
|
-$178M |
| 5 |
Goldman Sachs
New York
|
-$170M |
GSK Hedge Fund Activity: Q2 2026 in Review
1,050 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2026, worth a combined $18.2B — down 12% from $20.7B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new GSK positions and 87 closed out — a net gain of 7 holders — while 378 added to existing stakes and 347 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $140M. The largest seller was Dodge & Cox, cutting an estimated $553M.
- 1,050 institutional investors held GSK (GSK) as of Q2 2026, up from 1,043 in Q1 2026.
- Funds reported $18.2B of GSK stock for Q2 2026, down 12% quarter-over-quarter.
- 94 funds opened new GSK positions in Q2 2026 and 87 closed out, a net change of +7 holders.
- The largest GSK buyer in Q2 2026 was Point72 Asset Management, an estimated $140M added.
- The largest GSK seller in Q2 2026 was Dodge & Cox, an estimated $553M sold.
Based on aggregated 13F filings for Q2 2026.